Search research articles
Contact Us
Filters
Showing results (121-130 of 266) with videos related to
Page
of 27
Sort By:
The Lancet. Oncology
|
October 3, 2017
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
Arjun V Balar, Daniel Castellano, Peter H O'Donnell, et al.
Journal of Translational Medicine
|
August 21, 2016
Type 2 diabetes is associated with decreased PGC1α expression in epicardial adipose tissue of patients with coronary artery disease
Inmaculada Moreno-Santos, Luis Miguel Pérez-Belmonte, Manuel Macías-González, et al.
The Oncologist
|
July 26, 2022
Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma
Cristiane Bergerot, Sun Young Rha, Sumanta Pal, et al.
The Oncologist
|
May 8, 2026
The combination of atezolizumab and BCG in high-risk non-muscle invasive bladder cancer: results of the phase Ib/II BladderGATE clinical trial
Félix Guerrero-Ramos, Carmen Gómez-Cañizo, Marta Rodríguez-Izquierdo, et al.
Plos One
|
February 29, 2020
miRNA profiling in renal carcinoma suggest the existence of a group of pro-angionenic tumors in localized clear cell renal carcinoma
Lucía Trilla-Fuertes, Natalia Miranda, Daniel Castellano, et al.
The Lancet. Oncology
|
May 29, 2025
Health-related quality of life, pain, and symptomatic skeletal events with [<sup>177</sup>Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial
Karim Fizazi, Michael J Morris, Neal D Shore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 9, 2018
Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial
Bernard Escudier, Thomas Powles, Robert J Motzer, et al.
The Lancet. Oncology
|
February 14, 2022
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial
Antoine Thiery-Vuillemin, Johann de Bono, Maha Hussain, et al.
Environmental Research
|
January 28, 2023
Cross-sectional associations of persistent organic pollutants measured in adipose tissue and metabolic syndrome in clinically diagnosed middle-aged adults
Iris Reina-Pérez, Francisco Artacho-Cordón, Vicente Mustieles, et al.
Clinical Epigenetics
|
October 13, 2015
Analysis of the Polycomb-related lncRNAs HOTAIR and ANRIL in bladder cancer
Mónica Martínez-Fernández, Andrew Feber, Marta Dueñas, et al.
Page
of 27
Search research articles
Search
Showing results (121-130 of 266) with videos related to
Sort By:
Page
of 27
The Lancet. Oncology
|
October 3, 2017
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
Arjun V Balar, Daniel Castellano, Peter H O'Donnell, et al.
Journal of Translational Medicine
|
August 21, 2016
Type 2 diabetes is associated with decreased PGC1α expression in epicardial adipose tissue of patients with coronary artery disease
Inmaculada Moreno-Santos, Luis Miguel Pérez-Belmonte, Manuel Macías-González, et al.
The Oncologist
|
July 26, 2022
Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma
Cristiane Bergerot, Sun Young Rha, Sumanta Pal, et al.
The Oncologist
|
May 8, 2026
The combination of atezolizumab and BCG in high-risk non-muscle invasive bladder cancer: results of the phase Ib/II BladderGATE clinical trial
Félix Guerrero-Ramos, Carmen Gómez-Cañizo, Marta Rodríguez-Izquierdo, et al.
Plos One
|
February 29, 2020
miRNA profiling in renal carcinoma suggest the existence of a group of pro-angionenic tumors in localized clear cell renal carcinoma
Lucía Trilla-Fuertes, Natalia Miranda, Daniel Castellano, et al.
The Lancet. Oncology
|
May 29, 2025
Health-related quality of life, pain, and symptomatic skeletal events with [<sup>177</sup>Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial
Karim Fizazi, Michael J Morris, Neal D Shore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 9, 2018
Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial
Bernard Escudier, Thomas Powles, Robert J Motzer, et al.
The Lancet. Oncology
|
February 14, 2022
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial
Antoine Thiery-Vuillemin, Johann de Bono, Maha Hussain, et al.
Environmental Research
|
January 28, 2023
Cross-sectional associations of persistent organic pollutants measured in adipose tissue and metabolic syndrome in clinically diagnosed middle-aged adults
Iris Reina-Pérez, Francisco Artacho-Cordón, Vicente Mustieles, et al.
Clinical Epigenetics
|
October 13, 2015
Analysis of the Polycomb-related lncRNAs HOTAIR and ANRIL in bladder cancer
Mónica Martínez-Fernández, Andrew Feber, Marta Dueñas, et al.
Page
of 27